EntreChem closed a financing round totaling 1 million EUR ($1.25M) with existing shareholders of the company. This all-private funding significantly strengthens the capacities of research and development of the biotech company. These capital contributions help keep 100% ownership under local control, with Francisco Moris confirmed as Managing Director of the firm.
The capital raised represents a firm commitment by private investors with EntreChem’s future development plans. The funds will help complete preclinical studies of EC-8042 and EC-70124, the company two leading drugs in oncology, and help position the company for clinical trials.
About EntreChem SL is focused on the discovery and development of new drugs by bacterial genetic engineering and biocatalysis, and maintains collaborations with high-level academic labs in Europe and the USA for oncology development.
More information:
EntreChem SL: www.entrechem.com
